|

CC-99282 Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: BMS-986369

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Genmab1
  • Celgene1

Indications

  • Cancer2
  • Lymphoma, B-Cell1
  • Non-hodgkin Lymphoma1

Birmingham, Alabama1 trial

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Local Institution - 162

Phase 1

Tucson, Arizona1 trial

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

The University of Arizona Cancer Center - North Campus /ID# 242219

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.